Skip to main content

Advertisement

SpringerLink
Log in

Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696–1705

    Article  CAS  Google Scholar 

  2. Ahren B et al. (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27: 2874–2880

    Article  CAS  Google Scholar 

  3. Charbonnel B et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29: 2638–2643

    Article  CAS  Google Scholar 

  4. Ahren B (2007) DPP-4 inhibitors—clinical data and clinical implications. Diabetes Care [10.2337/dc07-0233v1-0]

  5. Nathan DM (2007) Finding new treatments for diabetes—how many, how fast... How good? N Engl J Med 356: 437–440

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice. R Retnakaran thanks Dr Daniel Drucker for helpful discussion and guidance.

Author information

Author notes

  1. Leadership Sinai Centre for Diabetes, 60 Murray Street, Suite L5-039, Mailbox 21, Toronto, ON M5T 3L9, Canada rretnakaran@mtsinai.on.ca

Authors and Affiliations

  1. R Retnakaran is an Assistant Professor in the Department of Medicine and Division of Endocrinology and Metabolism, University of Toronto, ON, Canada.,

    Ravi Retnakaran

Authors
  1. Ravi Retnakaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Retnakaran has received research funding from Merck Frosst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Retnakaran, R. Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?. Nat Rev Endocrinol 3, 572–573 (2007). https://doi.org/10.1038/ncpendmet0552

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0552

  • Springer Nature Limited

Search

Navigation